Case histories, magic bullets and the state of drug discovery

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 • 10,779 citations

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

2005 • 5,086 citations

Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis

2000 • 4,048 citations

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1993 • 3,605 citations

Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis

2000 • 3,176 citations

Cyclooxygenases: Structural, Cellular, and Molecular Biology

2000 • 2,837 citations

CYCLOOXYGENASES 1 AND 2

1998 • 2,700 citations

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

2004 • 2,481 citations

Protein kinases — the major drug targets of the twenty-first century?

2002 • 2,101 citations

Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

2005 • 2,039 citations

TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue

1991 • 1,814 citations

Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin

1992 • 1,711 citations

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.

1993 • 1,655 citations

The Coxibs, Selective Inhibitors of Cyclooxygenase-2

2001 • 1,563 citations

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

2002 • 1,349 citations

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2003 • 1,228 citations

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1998 • 990 citations

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

2003 • 898 citations

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

2004 • 711 citations

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia

2003 • 652 citations

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

2004 • 595 citations

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

2004 • 442 citations

The development of COX2 inhibitors

2003 • 438 citations

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery

2003 • 403 citations

Drug research: myths, hype and reality

2003 • 347 citations

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

2005 • 298 citations

Can cell systems biology rescue drug discovery?

2005 • 275 citations

COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

2006 • 270 citations

Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

2003 • 243 citations

The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin.

1998 • 204 citations

Rescuing drug discovery: in vivo systems pathology and systems pharmacology

2005 • 200 citations

Activation of Tyrosine Kinases in Cancer

2003 • 197 citations

Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation

1989 • 154 citations

Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis

1997 • 118 citations

Targeting protein kinases

2004 • 116 citations

Cyclooxygenase-2 as a therapeutic target

1998 • 77 citations

Bevacizumab

2005 • 75 citations

Structural Rearrangements in the Transmembrane Glycoprotein after Receptor Binding

1994 • 63 citations

Natalizumab

2005 • 21 citations

Third Tysabri adverse case hits drug class

2005 • 15 citations

Steven Nissen

2006 • 1 citations